Melatonin Supplementation Improves Glycemic Control While Lowering Oxidative Stress in Type 2 Diabetes

The purpose of this investigation was to evaluate the effect of melatonin on glycemic control and oxidative stress (OS) in adults with type 2 diabetes (T2D). Fourteen subjects with T2D (10 female, 4 male; 52.5 ± 5.0 years) were randomly assigned to melatonin (MEL) or placebo groups (PLA) for 42 days, in a crossover design. Subjects ingested 10 mg of MEL or an identical placebo (PLA) 30 minutes prior to sleep. Fasting blood draws occurred at baseline, 42 days, and 84 days. Plasma malondialdehyde, a marker of OS, significantly decreased on MEL (-6.25±2.10 nmol/ml) compared to PLA (0.72±3.30, p=0.028). The change in hemoglobin A1c showed a total improvement of 0.33% following MEL supplementation compared to PLA (-0.24±0.23 % for MEL vs. 0.09±0.21 % for PLA, p=0.01), although no significant changes were noted in fasting plasma glucose or lipid levels. Daily melatonin may diminish OS and enhance glycemic control in adults with T2D